ARTICLE | Finance
Making the Milestone
Canada-U.S. syndicate back Milestone Pharma's oral drug for cardiac arrhythmia
June 20, 2011 7:00 AM UTC
The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended to help develop an oral candidate to treat a form of cardiac arrhythmia.
BDC and fellow new investors Pappas Ventures and GO Capital led the cross-border syndicate. Fonds de solidarite FTQ, also a new investor, joined existing investors iNovia Capital and Fonds Bio-Innovation...